Fjorda Koromani1,2, Samuel Ghatan1,3, Mandy van Hoek1, M Carola Zillikens1, Edwin H G Oei2, Fernando Rivadeneira1,3, Ling Oei4,5,6. 1. Department of Internal Medicine, Erasmus University Medical Center, PO Box 2040-Na27-24, 3000 CA, Rotterdam, The Netherlands. 2. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. 4. Department of Internal Medicine, Erasmus University Medical Center, PO Box 2040-Na27-24, 3000 CA, Rotterdam, The Netherlands. h.l.d.w.oei@erasmusmc.nl. 5. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. h.l.d.w.oei@erasmusmc.nl. 6. Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands. h.l.d.w.oei@erasmusmc.nl.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk in individuals with diabetes mellitus. RECENT FINDINGS: Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals with T2DM. Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.
PURPOSE OF REVIEW: The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk in individuals with diabetes mellitus. RECENT FINDINGS: Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals with T2DM. Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.
Authors: Ling Oei; Fjorda Koromani; Stephan J Breda; John T Schousboe; Emma M Clark; Joyce Bj van Meurs; M Arfan Ikram; Jan H Waarsing; Frank Ja van Rooij; Maria C Zillikens; Gabriel P Krestin; Edwin Hg Oei; Fernando Rivadeneira Journal: J Bone Miner Res Date: 2017-09-06 Impact factor: 6.741
Authors: Nicola Napoli; Elsa S Strotmeyer; Kristine E Ensrud; Deborah E Sellmeyer; Douglas C Bauer; Andrew R Hoffman; Thuy-Tien L Dam; Elizabeth Barrett-Connor; Lisa Palermo; Eric S Orwoll; Steven R Cummings; Dennis M Black; Ann V Schwartz Journal: Diabetologia Date: 2014-06-09 Impact factor: 10.122
Authors: Veerle van Hulten; Cindy Sarodnik; Johanna H M Driessen; Nicolaas C Schaper; Piet P M M Geusens; Carol A B Webers; Geert-Jan Dinant; Ramon P G Ottenheijm; Nicklas H Rasmussen; Rikke Viggers; Coen D A Stehouwer; Carla J H van der Kallen; Miranda T Schram; Sandrine P G Bours; Pieter C Dagnelie; Joop P van den Bergh Journal: Front Endocrinol (Lausanne) Date: 2022-02-18 Impact factor: 5.555